Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
Most Cited Paper
in Immunotherapy and Immune Responses
18 Months Post-Publication
Class of 2026
“Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026/
Topics
hepatocellular carcinoma · personalized neoantigen vaccine · pembrolizumab · PD-1 inhibition · GNOS-PV02 · DNA plasmid vaccine · interleukin-12 · Tyrosine kinase inhibitor · neoantigen-specific T cell responses · Enzyme-linked immunosorbent spot assay · CD4+ effector T cells · CD8+ effector T cells · T cell receptor β-chain sequencing · vaccine-enriched T cell clone expansion · immune cell infiltration · single-cell analysis · cytotoxic T cell phenotypes · TCR complementarity-determining region cloning · Objective response rate (ORR) · complete response
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026. https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026. Accessed 2026-07-20. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459